Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.

PROBLEM/CONDITION Acquired immunodeficiency syndrome (AIDS)-defining opportunistic illnesses (OIs) are the major cause of morbidity and mortality among persons infected with human immunodeficiency virus (HIV). As a result of new treatments that reduce mortality for persons with AIDS, the number of persons living with AIDS is increasing, and the incidence of AIDS is decreasing. In 1997, an estimated 271,245 persons were living with AIDS in the United States and thus were at high risk for OIs. In 1997, an estimated 21,909 HIV-infected persons died with AIDS, nearly all as a result of OIs. REPORTING PERIOD COVERED Aggregate data and trends for 1992-1997 were examined to determine a) the frequencies at which OIs occurred first; b) the incidence of OIs; c) the percentage of persons among those who have died who had had a given OI during their course of AIDS, and d) the frequency of prescriptions for antiretroviral therapy and prophylaxis for Pneumocystis carinii pneumonia (PCP) and for Mycobacterium avium complex disease (MAC). DESCRIPTION OF SYSTEM Data were analyzed from the Adult/Adolescent Spectrum of HIV Disease (ASD) sentinel surveillance project, a prospective medical record review of HIV-infected persons aged > or = 13 years conducted in 11 U.S. cities. ASD data were standardized to national AIDS surveillance data for 1992-1997 by age; race; sex; country of birth; year of AIDS diagnosis; HIV exposure mode; and for incidence calculations, by CD4+ T-lymphocyte distribution. RESULTS The incidence declined significantly for each of 15 of the 26 specific AIDS-defining OIs (p<0.05). PCP was the most common AIDS-defining OI to occur first (PCP was the first OI to occur for 36% of HIV-infected persons), the most common incident AIDS-defining OI (274 cases per 1000 person-years), and the most common AIDS-defining OI to have occurred during the course of AIDS (53% of persons who died with AIDS had PCP diagnosed at some time during their course of AIDS). Of persons with CD4+ T-lymphocyte counts <500 cells/microL, the number with prescriptions for triple combination therapy increased from zero in 1992 to 40% in 1997, and 80% of persons had a prescription for any antiretroviral therapy in 1997. Of persons with CD4+ T-lymphocyte counts <200 cells/microL, the percentage with prescriptions for PCP prophylaxis remained stable from 1992 through 1997 (range: 75% to 80%). Of persons with CD4+ T-lymphocyte counts <50 cells/microL, the percentage with prescriptions for MAC prophylaxis increased from 9% in 1992 to 44% in 1997. INTERPRETATIONS The incidences of many OIs are decreasing primarily because of advances in HIV-related therapy. However, OIs are still occurring, especially when patients access care late during the course of disease. Even after accessing care, persons may develop OIs because of lack of prescription for prophylaxis, antiretroviral drug resistance, or poor adherence to therapy. During 1992-1997, most patients in need of PCP prophylaxis received a prescription for it; however, even in 1997, most patients in need of MAC prophylaxis did not receive a prescription for it. ACTIONS TAKEN These surveillance data are used by persons involved with developing guidelines for preventing OIs to determine the importance of and trends in OIs and preventive therapy. CDC is developing population-based approaches for surveillance of HIV disease progression, OIs, and therapies with the goal of making these data available in more geographic areas to help assess public health and health-care programs.

[1]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[2]  J. Ward,et al.  Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. , 1998, The Journal of infectious diseases.

[3]  M. Feinberg,et al.  Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Vol. 47/No. RR-5. , 1998 .

[4]  C. Beard,et al.  Opportunistic Infections (OIs) as Emerging Infectious Diseases: Challenges Posed by OIs in the 1990s and Beyond , 1998 .

[5]  J. Ward,et al.  Estimating the number of AIDS-defining opportunistic illness diagnoses from data collected under the 1993 AIDS surveillance definition. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[6]  G. Lemp,et al.  Prevention of Pneumocystis carinii pneumonia: who are we missing? , 1997, AIDS.

[7]  J. Ward,et al.  Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends , 1996, AIDS.

[8]  J. Ward,et al.  Tuberculosis among AIDS patients in the United States, 1993. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[9]  R. Chaisson,et al.  Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort , 1996, Annals of Internal Medicine.

[10]  David R. Holtgrave,et al.  USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: A Summary , 1996, Annals of Internal Medicine.

[11]  K. Holmes,et al.  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  S. Spector,et al.  A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. , 1995, The New England journal of medicine.

[13]  J. Phair,et al.  Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3. Multicenter AIDS Cohort Study. , 1994, The Journal of infectious diseases.

[14]  J. Ward,et al.  Surveillance of AIDS‐defining conditions in the United States , 1994, AIDS.

[15]  S. Buchbinder,et al.  Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS. , 1994, The Journal of infectious diseases.

[16]  É. Oksenhendler,et al.  Toxoplasma gondii infection in advanced HIV infection , 1994, AIDS.

[17]  R. Chaisson,et al.  Racial differences in the use of drug therapy for HIV disease in an urban community. , 1994, The New England journal of medicine.

[18]  J P Matts,et al.  Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, The Journal of infectious diseases.

[19]  K. Castro,et al.  Gender differences in reported AIDS-indicative diagnoses. , 1993, The Journal of infectious diseases.

[20]  J. Ward,et al.  Epidemiology of extrapulmonary tuberculosis among persons with AIDS in the United States. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Phair,et al.  Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. , 1993, American journal of epidemiology.

[22]  C. Reed,et al.  Spectrum of disease in persons with human immunodeficiency virus infection in the United States. , 1992, JAMA.

[23]  D. Vlahov,et al.  Sexually transmitted diseases in a population of intravenous drug users: association with seropositivity to the human immunodeficiency virus (HIV). , 1991, The Journal of infectious diseases.

[24]  M. Chiasson,et al.  Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). , 1991, AIDS.

[25]  P. Selwyn,et al.  Risk factors for human immunodeficiency virus infection in intravenous drug users. , 1989, The New England journal of medicine.

[26]  K. Mayer,et al.  Natural history of acquired immunodeficiency syndrome in women in Rhode Island. , 1989, The American journal of medicine.

[27]  Owen Devine,et al.  Predicting AIDS incidence by extrapolating from recent trends , 1989 .

[28]  Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. , 1989, MMWR supplements.

[29]  R. Selik,et al.  Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. , 1987, AIDS.

[30]  R. Redfield,et al.  Chronic vaginal candidiasis in women with human immunodeficiency virus infection. , 1987, JAMA.